
Dupixent Is Linked to a Higher Risk of Psoriasis in Patients With Atopic Dermatitis
Patients with atopic dermatitis (AD) who were treated with Dupixent (dupilumab) had a 58% higher three-year risk of developing psoriasis compared to those receiving other non-topical therapies, according to a recent study published in JAMA Dermatology. …